CLEAR CELL RENAL CELL CARCINOMA
Clinical trials for CLEAR CELL RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CLEAR CELL RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CLEAR CELL RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Two-Pronged immune attack shrink kidney tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving a combination of an experimental immunotherapy (epalolitoworelimab) and a targeted therapy (lenvatinib) before and after surgery can improve outcomes for people with high-risk clear cell kidney cancer. The treatment is given first to shrink th…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Drug cocktail aims to shrink kidney tumors before surgery and prevent return
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of two drugs—zanzalintinib (a pill taken daily) and pembrolizumab (given by IV every three weeks)—can shrink advanced kidney tumors before surgery and help prevent the cancer from coming back afterward. The study enrolls people …
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo may help more kidney cancer patients avoid full kidney removal
Disease control Not yet recruitingThis study tests whether giving a combination of two drugs (a PD-L1 inhibitor called TQB2450 and anlotinib) before surgery can shrink complex kidney tumors enough to allow surgeons to remove only the tumor and save the rest of the kidney. About 33 adults with advanced clear cell …
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail aims to shrink kidney tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New immunotherapy combo aims to boost kidney cancer surgery success
Disease control Not yet recruitingThis pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery …
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to shrink advanced liver and kidney tumors
Disease control Not yet recruitingThis study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail aims to shrink kidney tumors after first treatment fails
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to shrink liver tumors in kidney cancer patients
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New immunotherapy combo aims to fight advanced kidney cancer
Disease control Not yet recruitingThis study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:32 UTC
-
Mayo clinic tests urine and blood for kidney cancer clues
Diagnosis Not yet recruitingThis study looks for protein markers in urine and blood that could help identify different types of kidney cancer without needing a biopsy. Researchers will analyze stored urine samples from 300 people and collect blood before and after kidney removal surgery. The goal is to deve…
Matched conditions: CLEAR CELL RENAL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC